Print this page
Radiation
-
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Protocol: 112409Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis.
Protocol: 112506Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Other Hematopoietic -
A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features.
Protocol: 112509Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
Bright IDEAS-Young Adults: Problem-Solving Skills Training to Reduce Distress Among Young Adults with Cancer.
Protocol: 131911Principal Investigator:
- Katie Devine
Applicable Disease Sites: Any Site -
Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.
Protocol: 142202Applicable Disease Sites: Brain and Nervous System
-
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases.
Protocol: 142302Principal Investigator:
- Nicholas DeNunzio
Applicable Disease Sites: Brain and Nervous System -
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases.
Protocol: 142403Applicable Disease Sites: Brain and Nervous System
-
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases: A Phase II Study.
Protocol: 152201Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Any Site -
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.
Protocol: 152301Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumamb in Advanced Cancers.
Protocol: 172401Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Any Site -
Palbociclib and Binimetinib in RAS-Mutant Cancers.
Protocol: 172403Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.
Protocol: 172404Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach